Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674115 | 0.79 | APOBEC3A (0.47) | APOBEC3AAPOBEC3GKDM4ENPC1LMNA | |
| SCHEMBL2673093 | 0.76 | APOBEC3A (0.33) | APOBEC3AAPOBEC3GGRM1PIK3R1PIK3CA | |
| SCHEMBL2672868 | 0.73 | BRD4 (0.37) | APOBEC3AAPOBEC3GKDM4EGRM1RAB9A | |
| SCHEMBL2672881 | 0.73 | APOBEC3A (0.38) | APOBEC3AAPOBEC3GKDM4ENPC1LMNA | |
| SCHEMBL2673740 | 0.72 | APOBEC3A (0.37) | APOBEC3AAPOBEC3GPDE10AKDM4ENPC1 | |
| SCHEMBL2673340 | 0.72 | MAPT (0.39) | APOBEC3AAPOBEC3GKDM4ENPC1LMNA | |
| SCHEMBL2673810 | 0.70 | HSD17B10 (0.40) | APOBEC3AAPOBEC3GKDM4EGRM1SMN1; SMN2 | |
| SCHEMBL5709766 | 0.69 | SMPD3 (0.38) | APOBEC3AAPOBEC3GKDM4EGRM1ALDH1A1 | |
| SCHEMBL2673449 | 0.69 | CYP3A4 (0.34) | KDM4ENPC1LMNARAB9AALDH1A1 | |
| SCHEMBL2673201 | 0.69 | RAB9A (0.42) | KDM4ENPC1LMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311231-B1 | AGENT FOR COLOURING KERATIN-CONTAINING FIBRES COMPRISING AT LEAST ONE OXOCYCLOPENTENE DERIVATIVE | HENKEL KGAA (DE) | 2006-11-22 | — | — | EP | claimed |
| EP-1199065-A2 | Hair dye | Henkel Kommanditgesellschaft auf Aktien (DE) | 2002-04-24 | — | — | EP | claimed |
| EP-1732896-B1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8173682-B2 | Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1732896-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097750-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP3 | APOBEC3A 200/4885APOBEC3G 366/4885PDE10A 2650/4885 |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP3 | APOBEC3A 200/4885APOBEC3G 366/4885PDE10A 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.